)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Stille
Stille (STIL) investor relations material
Stille Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary23 Oct, 2026
Executive summary
Q3 net sales were MSEK 170.6, up 22.9% YoY, with 16.5% organic growth; EBIT margin before non-recurring items rose to 14.4% from 12.5%.
Rolling 12-month sales reached MSEK 711.4, exceeding MSEK 700 for the first time.
Improved availability and shorter delivery times supported growth; operating cash flow rose to MSEK 34 from MSEK 10.
Financial highlights
Q3 revenue was MSEK 170.6, up 22.9% YoY; constant-currency growth was 21.5%, including 16.5% organic growth.
EBITDA before non-recurring items rose 29% to MSEK 33.7; EBIT before non-recurring items rose 42% to MSEK 24.5.
Gross margin was 49.9%, or 50.5% excluding acquisition effects, with improvement mainly from favorable mix.
Operating cash flow was MSEK 34 versus MSEK 10 in Q3 2025; Jan-Sep operating cash flow was MSEK 91.2.
Jan-Sep sales were MSEK 536.5 versus MSEK 392.7; profit after tax was MSEK 66.0 versus MSEK 25.5.
Outlook and guidance
Long-term targets remain 10% organic growth, a 25% EBITDA margin and net debt/EBITDA below 3x.
Priorities include scaling instrument supply, strengthening commercial execution and customer access, and building capabilities and infrastructure for growth.
Plans include building on imagiQ3 momentum, pursuing share gains and complementing organic growth through selective acquisitions.
Tables growth of ~30% in 2026 is not expected to repeat in 2027; further growth and share gains remain the aim.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Stille
- Premium surgical instruments and tables drive strong growth and global expansion.STIL
Company presentation - Record Q2 2026 sales and profit growth driven by strong demand and operational execution.STILQ2 2026
- Strong financial growth and premium positioning drive expansion in surgical instruments and tables.STILCompany presentation
- Premium surgical solutions provider achieves strong growth and margins, expanding via acquisitions.STILInvestor presentation
- Q1 2026 saw 39% revenue growth and margin expansion, driven by demand and strategic acquisition.STILQ1 2026
- Q4 sales up 8.5% with strong surgical tables demand; outlook for 2026 remains positive.STILQ4 2025
- Sales rose 8.5% in Q3, but margins fell; supply chain and growth outlook improve for 2026.STILQ3 2025
- Sales declined 12.6% but margin and order intake improved; UK acquisition to boost growth.STILQ2 2025
- Q3 sales surged 82% with margin gains, led by Fehling integration and strong instrument growth.STILQ3 2024
Next Stille earnings date
Q4 202611 Feb, 2027
Stille
Next Stille earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Stille AB is a Swedish company specializing in the development, manufacture, and marketing of surgical instruments and medical equipment. Its product portfolio is divided into two main areas: surgical instruments and patient positioning tables. In the surgery business, Stille produces handcrafted instruments designed for open surgery, particularly in fields such as cardiovascular surgery and plastic surgery. Key products include scissors, forceps, clamps, and needle holders. The patient positioning division focuses on procedure-specific operating tables, including C-arm tables, used in various medical procedures like fluoroscopy, neurosurgery, and gynecology. The company is headquartered in Torshälla, Sweden, and its shares are listed on the Nasdaq Stockholm.